A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 24 Nov 2017
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms ASPIRE
- Sponsors Amgen; Onyx Pharmaceuticals
- 18 Nov 2017 Planned End Date changed from 1 Sep 2017 to 7 Dec 2017.
- 06 Nov 2017 This trial has been completed in Czech Republic.
- 06 Sep 2017 The study has been completed in Germany and Bulgaria.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History